Bavarian Nordic A/S – Notice Convening Annual General Meeting
COPENHAGEN, Denmark, March 21,
2024 – Pursuant to Articles 10-14 of the Articles of
Association, the shareholders of Bavarian Nordic A/S are hereby
convened to the Annual General Meeting to be held on
Tuesday, 16 April 2024, at 4 PM
CEST
at Comwell Borupgaard, Nørrevej 80, DK-3070
Snekkersten, Denmark with the following agenda:
- The Board of Directors' report on the Company's activities in
the past year.
- Presentation of the Annual Report for adoption.
- A proposal from the Board of Directors regarding the
application of profit or covering of loss pursuant to the Annual
Report as adopted.
- Presentation of and indicative vote on the Remuneration
Report.
- A resolution to discharge the Board of Directors and the Board
of Management from liability.
- Election of members of the Board of Directors.
- Election of Auditors.
- Any proposal from the Board of Directors or shareholders.
The Board of Directors has proposed the
following resolutions:
- Proposal to authorize the Board of Directors during the period
until 30 June 2025 to increase the share capital of the Company by
up to nominally DKK 78,097,830, corresponding to 10 % of the
Company's share capital.
- Proposal to authorize the Board of Directors during the period
until 30 June 2025 to obtain loans against issuance of convertible
notes which give the right to subscribe for new shares in the
Company and so that the Board of Directors is authorized to
increase the share capital of the Company by up to nominally DKK
78,097,830, corresponding to 10 % of the Company's share capital.
When exercising the authorizations proposed in items 8a and 8b, the
Board of Directors is in total authorized to increase the share
capital of the Company with a total of up to nominally DKK
78,097,830 (7,809,783 shares of DKK 10 each).
- Proposal to authorize the Board of Directors during the period
until 31 December 2025 to issue warrants, which entitle the holders
to subscribe for shares in the Company at a nominal value of up to
DKK 20,000,000 and to include in the authorization that the number
of shares may be higher or lower due to subsequent adjustments of
the warrants in accordance with the adjustment clauses determined
by the Board of Directors when the warrants are issued. Warrants
may only be granted to members of the Executive Management and to
employees of the Company or the Company's subsidiaries.
- Proposal to approve the Remuneration Policy.
- Proposal to approve remuneration of the Board of Directors and
the Board Committees for the current financial year.
- Proposal to authorize the Board of Directors to repurchase own
shares on behalf of the Company.
Elaboration on selected items of the
agenda:
Re 3) Proposal from the Board of Directors
regarding the application of profit or covering of loss pursuant to
the Annual Report as adoptedThe Board proposes to transfer the
Company’s result to 2024.
Re 4) Presentation of and indicative vote on the
Remuneration ReportThe Board proposes that the Remuneration Report
for 2023 is adopted.
Re 6) Election of Members of the Board of
DirectorsThe Board of Directors proposes that Luc Debruyne, Anders
Gersel Pedersen, Frank Verwiel, Anne Louise Eberhard, Heidi Hunter
and Johan van Hoof are re-elected. Peter Kürstein, member of the
Board, has informed the Board of Directors that he is not seeking
re-election. The Board proposes that Maria Montserrat Montaner
Picart is elected to the Board of Directors. If elected, the Board
of Directors will consist of 3 female and 4 male shareholder
elected board members.
The Recommendations on Corporate Governance
recommend that at least half of a company's board members elected
by the general meeting should be independent of the company. 6 out
of 7 of the nominated candidates are considered independent and as
such the Board of Directors will continue to meet the
recommendation, if elected.
The members of the Board of Directors are
proposed as follows:
Luc DebruyneChairman of the
board since 2023. Chair of the Nomination and Compensation
Committee since 2023 and member of the Science, Technology and
Investment Committee since 2023. Independent. Current term expires
in 2024. Mr. Debruyne is a Belgian national, born in 1963.
Luc Debruyne is former President Global Vaccines
at GSK where he was a member of GSK’s Corporate Executive Team, a
business leader with more than 30 years’ experience in the life
sciences industry.
Current positions: Professor of
Practice at the University of Leuven, Faculty of Medicine,
Biomedical Sciences Group and serves as non-executive director of
the board of University Hospitals UZ Leuven and Chair at Fund Plus.
Member of the Institutional Advisory Board at VIB, the Life
Sciences Board at Greenlight Biosciences Inc., Chair of the
Portfolio Strategy and Management Board of CEPI and Strategy
Advisor to the CEO.
Competences within: Corporate
Leadership, Life Sciences, Product Development and Supply,
Commercial Strategy, M&A and Business Development, Finance,
Capital and Risk Management, People and Culture and ESG.
Anders Gersel Pedersen, MD,
PhDMember of the board since 2010 and deputy Chair since
2014. Member of the Science Technology and Investment Committee
since 2020 and member of the Finance, Risk and Audit Committee
since 2022. Not independent. Current term expires in 2024. Dr.
Pedersen is a Danish national, born in 1951.
Former Executive Vice President of Research
& Development of H. Lundbeck A/S.
Current positions: Member of
the board of Genmab A/S, Hansa Biopharma AB and Bond Avillion 2, an
entity of Avillion LLP. Chairman of the board of Aelis Farma.
Dr. Pedersen is also the CEO in his private
holding company Gerselconsult ApS.
Competences within: Corporate
Leadership, Life Sciences, Product Development and Supply,
Commercial Strategy, M&A and Business Development, Finance,
Capital and Risk Management, People and Culture and ESG.
Frank Verwiel, MD, MBAMember of
the board since 2016. Member of the Nomination and Compensation
Committee since 2020 and the Science, Technology and Investment
Committee since 2022. Independent. Current term expires in 2024.Dr.
Verwiel is a Dutch national, now resident of the USA, born in
1962.
Former president and chief executive officer of
Aptalis Pharma, Inc.
Current positions: Chair of the
board of Intellia Therapeutics, Inc.
Competences within: Corporate
Leadership, Life Sciences, Commercial Strategy, M&A and
Business Development and People and Culture.
Anne Louise Eberhard, LL.M, Graduate
Diploma BAMember of the board since 2019. Chair of the
Finance, Risk and Audit Committee since 2020 and member of the
Nomination and Compensation Committee since 2023. Independent.
Current term expires in 2024. Ms. Eberhard is a Danish national,
born in 1963.
Former Senior Executive Vice President and
Global Head of Corporate & Institutional Banking at Danske Bank
A/S, and Chief Commercial Officer at Intrum AB.
Current positions: Chair of the
board of Finansiel Stabilitet SOV, Moneyflow Group A/S and its
subsidiary Moneyflow 1 A/S. Member of the board of FLSmidth &
Co. A/S and its subsidiary FLSmidth A/S, Simcorp A/S, Den Danske
Unicef Fond, Knud Højgaards Fond, and VL 52 ApS. Member of the
executive board of EA Advice ApS. Advisory Board Member of Center
for Strategisk CSRD, a Danish ESG initiative by EY and Axcelfuture,
and Faculty Member at Copenhagen Business School, Board
Educations.
Competences within: Corporate
Leadership, Commercial Strategy, M&A and Business Development,
Finance, Capital and Risk Management, People and Culture, ESG and
Technology and Digitalization.
Heidi Hunter, MBAMember of the
board since 2023. Chair of the Science, Technology and Investment
Committee since 2023. Independent. Current term expires in 2024.
Ms. Hunter is an American national, born in 1958.Heidi Hunter is
former President, Cardinal Health Specialty Solutions and has also
held positions as Senior Vice President in UCB and Boehringer
Ingelheim and as Vice President in IQVIA and Centocor (a Johnson
& Johnson Company).
Current Positions: Member of
the board of Vicore Pharma Holding AB, IO Biotech, Inc. and Sutro
BioPharma Inc.
Competences within: Corporate
Leadership, Life Sciences, Commercial Strategy, M&A and
Business Development, Finance, Capital and Risk Management, People
and Culture, ESG and Technology and
Digitalization.
Johan van Hoof, MD Member of
the board since 2023. Member of the Science Technology and
Investment Committee since 2023 and member of the Finance, Risk and
Audit Committee since 2023. Independent. Mr. van Hoof is a Belgian
national, born in 1957.
Former Global Therapeutic Area Head, Infectious
Diseases & Vaccines, R&D at Janssen, the pharmaceutical
division of Johnson & Johnson. Formerly Chief Operating
Officer, R&D of Johnson & Johnson pharmaceuticals. Before
joining Johnson & Johnson, Mr. Van Hoof acquired more
than 20 years of experience in the vaccine industry, having worked
with Pasteur Mérieux Connaught (today Sanofi Aventis), Chiron
Vaccines and GlaxoSmithKline (GSK) Biologicals. During this period,
he held leadership roles with increasing responsibilities covering
discovery, clinical development, QA-QC, and regulatory affairs.
Current positions: Working
through his private one-man company, he acts as independent advisor
for the biotech/vaccine industry and for not-for-profit
organizations/academia. This includes a role as (independent) Chief
Scientific advisor to Ziphius, a startup vaccine company focused on
self-amplifying mRNA-based vaccines, still at pre-clinical
stage.
Competences within: Corporate
Leadership, Life Science, Product Development and Supply,
Commercial Strategy, M&A and Business Development.
Maria Montserrat Montaner Picart (Montse
Montaner)Observer of the board since 2023. Independent.
Montse Montaner is a Spanish national, born in 1968.
Montse Montaner is former Chief Quality Officer
and the first Chief Sustainability Officer of Novartis where she
has held various leading positions. She has more than 30 years of
industry and executive experience and has received several
recognitions for her leadership in driving sustainable
organizations. Montse Montaner currently serves as a board member
of a Children’s Tumor Foundation and is member of the Advisory
Board and the Executive Council of 09 Solutions Inc.
Current position: CEO and
Founder of Montaner & Associates GmbH.
Competences within:
Corporate Leadership, Life Sciences, Product Development and
Supply, Finance, Capital and Risk Management, People and Culture
and ESG.
Re 7) Election of AuditorsThe Board of Directors
proposes that KPMG (CVR-nr. 25578198) is elected as the Company's
new auditor.
The Board of Directors further proposes that the
appointment of KPMG, as the Company’s auditor, includes the duty to
audit and provide statement of assurance on the Company’s
sustainability report.
Due to legal requirements the Company’s auditor
must be rotated at the general meeting in 2024. During the early
spring of 2023, the Company initiated the process to tender the
audit services in a tender process headed by the Finance, Risk and
Audit Committee in accordance with applicable law. The process was
based on a thorough evaluation of the received proposals and
meetings with the participating audit companies. The Finance, Risk
and Audit Committee ultimately decided in late 2023 to recommend to
the Board of Directors the election of KPMG as the Company’s new
auditor as KPMG best addressed and fulfilled the selection criteria
defined in the tender documents and possesses the required and
sufficient qualifications and competencies. Based on the
recommendation of the Finance, Risk and Audit Committee, the Board
of Directors proposes that KPMG is elected.
The Finance, Risk and Audit Committee has been
free from influence by a third party and has not been subject to
any contract with a third party restricting the choice by the
general meeting on the selection of a statutory auditor or an audit
firm.
Re 8a) Proposal to authorize the Board of
Directors to increase the share capitalThe Board of Directors
proposes that the Board of Directors in a new Article 5a,
subsections 1-3 of the Articles of Association, during the period
until 30 June 2025 is authorized to increase the share capital of
the Company in one or more issues by a total of up to nominally DKK
78,097,830, corresponding to 10 % of the Company's share capital.
The proposal entails amending Article 5a of the Articles of
Association as follows:
"Subsection 1For the period ending on 30 June
2025, the Board of Directors is authorized to increase the
Company's share capital in one or more issues with a total of up to
nominally DKK 78,097,830 (7,809,783 shares of DKK 10 each) by the
subscription of new shares. The existing shareholders shall have
pre-emption rights to subscribe for the amount by which the share
capital is increased, proportional to their shareholdings. The
share capital shall be increased by cash payment at a subscription
price which may be lower than the value of the shares.
The terms and conditions of the subscription for
shares shall be determined by the Board of Directors.
The new shares shall be negotiable instruments,
shall be registered in the names of the holders and shall be
entered in the Company's register of shareholders. No restrictions
shall apply to the transferability of the new shares, and no
shareholder shall be obliged to have his shares redeemed - in whole
or in part. The shares shall carry the right to dividend as from
the date fixed by the Board of Directors, but not later than the
first financial year following the capital increase.
Subsection 2For the period ending on 30 June
2025, the Board of Directors is authorized to increase the
Company's share capital in one or more issues with a total of up to
nominally DKK 78,097,830 (7,809,783 shares of DKK 10 each) by the
subscription of new shares. The existing shareholders shall not
have pre-emption rights to subscribe for the amount by which the
share capital is increased.
The share capital may be increased by cash
payment or in other ways, such as by conversion of debts or in
payment of a contribution in kind. The share capital shall in any
event be increased at a subscription price, which is not lower than
market value.
The terms and conditions of the subscription for
shares shall be determined by the Board of Directors.
The new shares shall be negotiable instruments,
shall be registered in the names of the holders and shall be
entered in the Company's register of shareholders. No restrictions
shall apply to the transferability of the new shares, and no
shareholder shall be obliged to have his shares redeemed - in whole
or in part. The shares shall carry the right to dividend as from
the date fixed by the Board of Directors, but not later than the
first financial year following the capital increase.
Subsection 3When exercising the authorizations
given in Articles 5a(1) and 5a(2) the Board of Directors is in
total authorized to increase the share capital of the Company with
a total of up to nominally DKK 78,097,830 (7,809,783 shares of DKK
10 each).”
Re 8b) Proposal to authorize the Board of
Directors to obtain loans against issuance of convertible notes
which give the right to subscribe for new shares in the CompanyThe
Board of Directors proposes that the Board of Directors in a new
Article 5a, subsection 4 of the Articles of Association during the
period until 30 June 2025 is authorized to obtain loans against
issuance of convertible notes which give the right to subscribe for
new shares in the Company and so that the Board of Directors is
authorized to increase the share capital of the Company by up to
nominally DKK 78,097,830, corresponding to 10 % of the Company's
share capital.
The proposal entails adding a new subsection 4
to Article 5a of the Articles of Association as follows:
“Subsection 4For the period ending on 30 June
2025, the Board of Directors is authorized to obtain loans in the
Company by issue of convertible notes that give the right to
subscribe for new shares in the Company by a maximum nominal value
of up to DKK 78,097,830. The Company's existing shareholders shall
not have pre-emption rights to grant loans. The loans shall be paid
in cash. The terms and conditions for the loans and the convertible
notes shall be determined by the Board of Directors.
As a consequence of the conversion of the
convertible notes, the Board of Directors is authorized for the
period ending 30 June 2025 to increase the Company's share capital
by a nominal value of up to DKK 78,097,830 (7,809,783 shares of DKK
10 each) in one or more portions by resolution of the Board of
Directors by conversion of the convertible notes and on such other
terms as the Board of Directors may determine. The Company’s
existing shareholders shall not have pre-emption right to subscribe
for shares issued by conversion of the convertible notes.
The new shares issued based on convertible notes
shall have the same rights as existing shares according to the
Articles of Association. The new shares shall be negotiable
instruments, shall be registered in the names of the holders and
shall be entered in the Company's register of shareholders. No
restrictions shall apply to the transferability of the new shares,
and no shareholder shall be obliged to have his shares redeemed -
in whole or in part. The new shares shall carry the right to
dividend from the time of conversion of the issued convertible
notes, i.e. from the time of subscription.”
The Board of Directors also proposes that
Article 5a subsection 3 is amended as follows:
“Subsection 3When exercising the authorizations
given in Articles 5a(1), 5a(2), and 5a(4) the Board of Directors is
in total authorized to increase the share capital of the Company
with a total of up to nominally 78,097,830 (7,809,783 shares of DKK
10 each).”
Re 8c) Proposal to authorize the Board of
Directors to issue warrants The Board of Directors proposes to
authorize the Board of Directors in a new Article 5b of the
Articles of Association, so that the Board of Directors until 31
December 2025 is authorized to issue warrants, which entitle the
holders to subscribe for shares in the Company at a nominal value
of up to DKK 20,000,000 (identical to nominally DKK 20,000,000 last
year). The Board of Directors also proposes to authorize the Board
of Directors to reuse or reissue any lapsed and unexercised
warrants under the terms and within the time limitations set out in
this authorization. The proposal entails authorizing the Board of
Directors to increase the share capital of the Company as a
consequence of the issuance of warrants until 1 April 2029.
Consequently, adding a new Article 5b to the Articles of
Association as follows:
"During the period ending 31 December 2025, the
Company may issue warrants, in one or more portions by resolution
of the Board of Directors. The warrants may be issued to the
management and employees of the Company or its subsidiaries for the
subscription of a nominal value of up to DKK 20,000,000 (2,000,000
shares of DKK 10 each), however, the number of shares may be higher
or lower due to subsequent adjustments of the warrants in
accordance with the adjustment clauses determined by the Board of
Directors when the warrants are issued. The warrants can be
exercised by cash contribution at a subscription price and on such
other terms as the Board of Directors may determine. Any issuance
of warrants to the management shall be made in accordance with the
Company's Remuneration Policy. Warrants may not be granted to
members of the Company's Board of Directors (except for employee
representatives (if such may have been elected) who receive
warrants in their capacity as employees of the Company or of the
Company's subsidiaries).
Holders of warrants shall have pre-emption right
to subscribe for the shares issued based on the warrants, meaning
that the pre-emption rights to subscribe to warrants and new shares
for existing shareholders are deviated from.
As a consequence of the exercise of awarded
warrants, the Board of Directors is authorized during the period
until 1 April 2029 to increase the share capital by a nominal value
of up to DKK 20,000,000 (2,000,000 shares of DKK 10 each) in one or
more portions by resolution of the Board of Directors by cash
contribution at a subscription price and on such other terms as the
Board of Directors may determine without pre-emption right for the
existing shareholders, however, the number of shares by which the
share capital may be increased may be higher or lower if the number
of warrants is increased in accordance with the adjustment clauses
determined by the Board of Directors when the warrants are
issued.
The new shares issued based on warrants shall
have the same rights as existing shares according to the Articles
of Association. The new shares shall be negotiable instruments,
shall be registered in the names of the holders and shall be
entered in the Company's register of shareholders. No restrictions
shall apply to the transferability of the new shares and no
shareholder shall be obliged to have his shares redeemed - in whole
or in part. The new shares shall carry the right to dividend from
the time of subscription.
Subject to the rules in force at any time, the
Board of Directors may reuse or reissue lapsed and unexercised
warrants if any, provided that the reuse or reissue occurs under
the terms and within the time limitations set out in this
authorization. Reuse is to be construed as the Board of Directors'
entitlement to let another party enter into an existing agreement
on warrants. Reissue is to be construed as the Board of Directors'
option to reissue new warrants, under the same authorization, if
previously issued warrants have lapsed."
Re 8d) Proposal to approve the Remuneration
PolicyThere are no proposed changes to the Remuneration Policy.
The Remuneration Policy in its entirety must be
submitted for approval by the shareholders at least every fourth
year. The Board proposes that the Remuneration Policy is approved
in its entirety. The Remuneration Policy was last approved in its
entirety at the general meeting in 2020.
The Remuneration Policy can be downloaded from
www.bavarian-nordic.com/agm.
Re 8e) Proposal to approve remuneration of the
Board of Directors and the Board Committees for the current
financial yearThe Board of Directors proposes to maintain the same
level of remuneration for the Board of Directors as was approved at
the annual general meeting in 2023, and as set out below:
The Board of Directors proposes that (i) the
annual base fee to members of the Board of Directors will be DKK
300,000; (ii) the remuneration to the Chair will be three times the
annual base fee equivalent to DKK 900,000; and (iii) the
remuneration to the Deputy Chair will be one point eight times the
annual base fee equivalent to DKK 540,000.
In addition to the base fee, the Board of
Directors proposes that the Board as part of the remuneration
receives Restricted Stock Units equal to 50% of the annual base fee
of DKK 300,000 (for the Chair, however, equivalent to 50% of three
times the annual base fee and for the Deputy Chair equivalent to
50% of one point eight times the base annual fee) in accordance
with the Company’s remuneration policy.
The Board of Directors further proposes that the
members of the three board committees will receive an additional
annual committee fee of DKK 120,000 per committee. The remuneration
to the Chair of the board committees will, however, be two times
the annual committee fee, thus DKK 240,000. The Board of Directors
has established a Finance, Risk and Audit Committee, a Nomination
and Compensation Committee and a Science, Technology and Investment
Committee.
Finally, the Board of Directors proposes that
each member of the Board of Directors receives (i) an attendance
fee of DKK 5,000 for each board and/or committee meeting he/she
attends to, which in no event can exceed DKK 5,000 per day or (ii)
for members of the Board of Directors, who travel overseas in order
to participate, a fee of USD 5,000. Furthermore, the Company pays
the travelling expenses incurred by the board members in connection
with board- and/or committee meetings, and any social costs
associated with the remuneration of the Board of Directors and the
board committees (e.g. mandatory contributions to social security
in other countries).
Re 8f) Proposal to authorize the Board of
Directors to purchase own shares on behalf of the CompanyThe Board
of Directors proposes that the Board of Directors is authorized on
behalf of the Company to acquire own shares in the Company.
It is therefore proposed that the following
authorization is granted to the Company’s Board of Directors
pursuant to Article 198 of the Danish Companies Act:
“The General Meeting hereby authorizes the Board
of Directors to acquire own shares on behalf of the Company in
accordance with Article 198 of the Danish Companies Act. The
Company may only acquire own shares for a total nominal value of up
to 10 % of the Company’s share capital for the time being. The
remuneration paid in connection with the acquisition of own shares
may not deviate by more than 10 % from the price of the Company's
shares on Nasdaq Copenhagen at the time of acquisition. This
authorization is granted to the Company’s Board of Directors for
the period until 31 December 2025."
* * * * * * * *
Majority requirementsAdoption
of the proposals referred to in items 1, 2, 3, 5, 6, 7, 8d, 8e, and
8f, requires a simple majority of votes. Item 4 requires an
indicative vote only.
Adoption of the proposals referred to in items
8a, 8b and 8c, requires a special majority, cf. Section 106 of the
Danish Companies Act and Article 16 of the Articles of Association.
According to this, the adoption of such proposals requires the
affirmative votes of at least two-thirds of the votes cast as well
as at least two-thirds of the votes represented at the General
Meeting.
Participation, admission cards and
voting rightsShareholders who wish to attend the General
Meeting must order admission cards no later than on 12 April 2024
at 11:59 PM CEST in accordance with Article 11 of the Articles of
Association. Please be informed that attendance requires ordering
an admission card prior to the General Meeting.
Admission cards will be provided to shareholders
who are entitled to attend and vote at the General Meeting. Anyone
who is registered as a shareholder in the register of shareholders
on the date of registration, 9 April 2024, or who has made a
request to such effect by that date is entitled to attend and vote
at the General Meeting.
Admission cards may be ordered electronically
from www.bavarian-nordic.com/agm via the Shareholder Portal or by
downloading and printing the order form, which is available on the
Company’s website. A duly completed request form may also be
submitted to Bavarian Nordic A/S’ Shareholder Register,
Computershare A/S, e-mail: gf@computershare.dk or by ordinary mail
to Computershare A/S, Lottenborgvej 26D 1 sal, 2800 Kgs. Lyngby,
Denmark. A request to participate may also be given to
Computershare A/S, by telephone: +45 45 46 09 97.
Admission cards will be sent to the email
address specified in the shareholder portal upon registration. The
admission card must be presented at the General Meeting either
electronically on a smartphone/tablet or printed.
Shareholders who have ordered admission cards
without specifying their e-mail address can pick up the admission
card at the entrance of the General Meeting upon presentation of ID
(for example a passport or driver’s license).
Ballots for voting at the General Meeting will
be handed out at the entrance.
Voting by proxyShareholders may
vote by proxy. An instrument of proxy issued to the Board of
Directors of the Company may only concern a specific General
Meeting with an agenda that is known in advance. Shareholders may
notify the Company electronically of the appointment of a proxy at
www.bavarian-nordic.com/agm or by completing and submitting a
written proxy form that can be downloaded on the Company’s website.
The form may be submitted as mentioned above and must be received
by the Company no later than 12 April 2024 at 11:59 PM CEST. The
proxy holder may also provide a written and dated instrument of
proxy at the General Meeting.
Postal votingIt is also
possible for shareholders to vote by post. Postal votes can be
submitted electronically via www.bavarian-nordic.com/agm or by
completing and submitting a postal voting form that can be
downloaded on the Company’s website. The form may be submitted as
mentioned above and must be received by the Company no later than
12 April 2024 at 11:59 PM CEST. Once the postal vote has been
received by the Company, the vote cannot be revoked by the
shareholder.
Written questionsShareholders
may submit questions in writing to the Company regarding the
agenda, the documents to be presented at the General Meeting or the
general position of the Company. Questions may be submitted by post
or e-mail to info@bavarian-nordic.com. Questions will be answered
at the General Meeting.
LanguageRepresentatives of the
Company will conduct the General Meeting in English. Shareholders
may choose whether to communicate in Danish or in English. During
the meeting, simultaneous interpretation from English to Danish and
Danish to English will be available.
WebcastThe Annual General
Meeting will be transmitted to shareholders via webcast on the
Shareholder portal, www.bavarian-nordic.com/agm. Shareholders who
wish to follow the webcast do not need to order admittance
card.
Information on the websiteThe
following documents and information will be available on the
Company's website at www.bavarian-nordic.com/agm, 21 March – 16
April 2024 (both days included): 1) The notice convening the
General Meeting; 2) The total number of shares and voting rights as
at the date of the convening notice; 3) All documents to be
submitted to the General Meeting, including the annual report for
2023 containing the audited annual and consolidated accounts etc.;
4) The agenda and the full text of all proposals to be submitted to
the General Meeting; and 5) Postal and proxy voting forms.
Share capitalThe Company’s
share capital amounts to nominally 780,978,340 divided into shares
in the denomination of DKK 1 and multiples thereof. Each share of a
nominal value of DKK 10 gives one vote.
Personal dataWith regards to
Bavarian Nordic's processing of personal data in connection with
general meetings, reference is made to Bavarian Nordic's Privacy
Policy which is available on the Company's website
www.bavarian-nordic.com.
About Bavarian NordicBavarian
Nordic is a fully integrated vaccine company with a mission to
protect and save lives through innovative vaccines. We are a global
leader in smallpox and mpox vaccines, supplied to governments to
enhance public health preparedness and have a strong portfolio of
vaccines for travelers and endemic diseases. For more information
visit www.bavarian-nordic.com.
Forward-looking statements This
announcement includes forward-looking statements that involve
risks, uncertainties and other factors, many of which are outside
of our control, that could cause actual results to differ
materially from the results discussed in the forward-looking
statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance
and/or other information that is not historical information. All
such forward-looking statements are expressly qualified by these
cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. We undertake no
obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made,
except as required by law.
ContactsEurope: Rolf Sass
Sørensen, Vice President Investor Relations, Tel: +45 61 77 47
43US: Graham Morrell, Paddock Circle Advisors,
graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 06 / 2024
Grafico Azioni Bavarian Nordic AS (TG:BV3)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Bavarian Nordic AS (TG:BV3)
Storico
Da Set 2023 a Set 2024